N
Neotract
Developing minimally invasive and clinically effective devices that address unmet needs in the field of urology, current focus on the UroLift system
About Neotract
NeoTract, Inc., founded in 2004 and headquartered in Pleasanton, California, specializes in medical devices aimed at addressing significant clinical needs. The company's flagship product, the UroLift System, is a minimally invasive permanent implant designed to treat men suffering from benign prostatic hyperplasia (BPH), commonly known as an enlarged prostate. This system offers rapid symptom relief and improved quality of life while preserving normal sexual function, a significant advantage over traditional treatments. NeoTract operates in the medical device market and serves healthcare providers and patients across the USA, Europe, Australia, Canada, Mexico, and South Korea. The company's business model revolves around direct sales and distributor partnerships in key global markets. Revenue is generated through the sale of the UroLift System and related medical devices. NeoTract's innovative approach and clinically proven solutions have led to the treatment of over 100,000 patients, establishing it as a leader in the BPH treatment space.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2004
- Headquarters
- Mountain View, United States
- Employees
- 161
- Open positions
- None listed
- Dealroom signal
- 66.0/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Non-Invasive medical devices and treatments, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Sep 2017 | $1.1B | — | Teleflex | — |
| LATE VCOther financing | Jan 2017 | $13M | $51M | Windham Venture Partners | — |
Growth signals
Latest recorded traffic for Neotract is 570 monthly website visits, down 62% over the last three months. Neotract's team declined 6.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Windham Venture Partners
Johnson & Johnson
Quadrille Capital
Series B and later2 investors entered at this stage
Other known investors1 additional known investor
Teleflex
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Neotract on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Neotract’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.